CD274 and neoplasm: PD-1:PD-L1 engagement inhibits the TCR-induced “stop signal,” resulting in reduced T-cell:DC or T-cell:tumor contact; PD-1 blockade may reverse these effects, abrogate tolerance, and improve tumor targeting (75, 76).